^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ONKT101

i
Other names: ONKT101
Associations
Trials
Company:
Avectas, ONK Therap
Drug class:
CD19 inhibitor, TRAIL R2 agonist
Related drugs:
Associations
Trials
over3years
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. (PubMed, Cancers (Basel))
Finally, we consider the broader landscape of competing immunotherapeutic approaches to AML treatment. In doing so we evaluate the innate potential, status and remaining barriers for CAR-NK based AML immunotherapy.
Review • Journal
|
CD19 (CD19 Molecule)
|
ONKT101